Qyuns Therapeutics Enters Development, Potential Commercialization Partnership for QX005N

MT Newswires Live07-22

Qyuns Therapeutics Enters Development, Potential Commercialization Partnership for QX005N Qyuns Therapeutics (HKG:2509) has granted Huadong Medicine's subsidiary Zhongmei Huadong the exclusive rights ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2453613887?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-22 20:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2453613887","market":"sh","top_or_hot":-1,"title":"Qyuns Therapeutics Enters Development, Potential Commercialization Partnership for QX005N","media":"MT Newswires Live","content":"<div>\n<p>Qyuns Therapeutics Enters Development, Potential Commercialization Partnership for QX005N Qyuns Therapeutics (HKG:2509) has granted Huadong Medicine's subsidiary Zhongmei Huadong the exclusive rights ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n","source":"mtnewswires_live","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Qyuns Therapeutics Enters Development, Potential Commercialization Partnership for QX005N</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQyuns Therapeutics Enters Development, Potential Commercialization Partnership for QX005N\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-22 20:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Qyuns Therapeutics Enters Development, Potential Commercialization Partnership for QX005N Qyuns Therapeutics (HKG:2509) has granted Huadong Medicine's subsidiary Zhongmei Huadong the exclusive rights ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2453613887","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2453613887","pubTimestamp":1721649899,"sourceInfo":{"source_id":"mtnewswires_live","name":"MT Newswires Live"},"weMediaInfo":null,"summary":"Qyuns Therapeutics Enters Development, Potential Commercialization Partnership for QX005N Qyuns Ther","collect":0,"end_time":0,"defaultTopTitle":"mtnewswires.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK1161":"生物科技","BK4526":"热门中概股","LENZ":"Therapeutics","BK4023":"应用软件","02509":"荃信生物-B","BK1153":"再保险","01508":"中国再保险","HKD":"尚乘数科","BK4139":"生物科技","BK1550":"内险股","BK4585":"ETF&股票定投概念"},"translate_title":"Qyuns Therapeutics进入QX005N的开发和潜在商业化合作伙伴关系","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01508":1,"02509":1,"HKD":1,"LENZ":1},"content_text":"Qyuns Therapeutics Enters Development, Potential Commercialization Partnership for QX005N Qyuns Therapeutics (HKG:2509) has granted Huadong Medicine's subsidiary Zhongmei Huadong the exclusive rights to jointly develop QX005N, and an optional right to market it in the field of healthcare in the greater China region, a Sunday filing with the Hong Kong Exchange said.QX005N is a monoclonal antibody (mAb) blocking IL-4RÎ± and has received up to seven Investigational New Drug Application approvals from relevant authorities for indications like atopic dermatitis, prurigo nodularis, and chronic rhinosinusitis with nasal polyps.Under the agreement, the parties will conduct the clinical and non-clinical studies and registration-related work of the subject product together and if Zhongmei agrees to market the product as well then it will be responsible for the marketing and promotion of the product in the greater China region.Cellularforce, a subsidiary of the company will produce the clinical trial samples of the product.The company's shares were up nearly 2% on Monday's close.Price (HKD): $20.10, Change: $+0.34, Percent Change: +1.72%","kind":null,"is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2453613887"}